UREA BREATH TEST MARKET ANALYSIS

The urea breath test is used to detect Helicobacter pylori (H. pylori), a type of bacteria that may infect the stomach and is a main cause of ulcers in both the stomach and duodenum (the first part of the small intestine).

In several countries, assessment studies are conducted for non-invasive ¹³C urea breath test (UBT) in comparison to other alternative tests such as endoscopy and stool antigen test. For instance, in July 2020, a pilot study was conducted in Alkarak teaching hospital, Jordan for understanding the benefits of UBT over other diagnostic tests for detecting H. pylori. The study concluded ¹³C UBT was more accurate and sensitive (94.1%) than the stool antigen test and can be a reliable substitute for invasive tests such as endoscopy.

Several studies are conducted for evaluating the efficiency of urea breath test for detection of Helicobacter pylori. For instance, in 2019, a multicenter clinical study was conducted by Exalenz Bioscience Ltd, Israel for analyzing the specificity and sensitivity of BreathID Hp Lab System. There are several advantages offered by the system such as continuous evaluation of breath samples in real-time point-of-care analyses along with providing accuracy of around >99% . Hence, such evaluation studies of urea breath test against histology and rapid urease test are contributing to its high adoption rate during the forecast period. 

The global urea breath test market is estimated to be valued at US$ 115.96 million in 2022 and expected to exhibit a CAGR of 5.4% over the forecast period (2022-2030)

Figure 1. Global Urea Breath Test Market Share (%) in Terms of Value, By Region, 2022

To learn more about this report, request sample copy

Increasing studies focused on urea breath test over histopathogical test for H. Pylori detection is expected to witness significant growth of the market in the future

For instance, in June 2021, a research study was published in Dove Press Ltd., which compared diagnostic value for 14C urea breath test in comparison to histopathology in Indonesian dyspeptic patients. The paper highlighted the fact that there is very limited number of hospitals with endoscopy system in Indonesia. Hence, alternative non-invasive methods such as urea breath test will be favorable alternative for covering Indonesian populations for diagnosing H. pylori.

Figure 2. Global Urea Breath Test Market Share (%), by Product, 2022

To learn more about this report, request sample copy

Global Urea Breath Test Market: Restraint

There are several diagnostic assays which can be used for detection of H. pylori infection. These are broadly divided into invasive methods and non-invasive methods. The invasive method used for evaluation of H. pylori consists of histopathological examination, molecular testing, and other culture-based tests, while non-invasive techniques includes urea breath test (UBT) and stool antigen test (SAT).

Hence, the presence of several alternative tests other than Urea Breath Test (UBT) for detection of H. pylori infection is a major factor hampering the market growth

In addition, there are certain limitations of UBT which has affected its adoption rate negatively. The following are the two major limitations of UBT:

• With the use of 13C-Urea Breath Test (UBT), frequently false-negative results are obtained owing to low bacterial loads in the stomach  mucosa
• The diagnosis with UBT also gives false-positive results when urease-producing bacterial species colonize the achlorhydric stomach due to atrophic gastritis or high use of proton pump inhibitors (PPIs)

Key Players

Major players operating in the global urea breath test market include Kibion AB (Mayoly Spindler), Avanos Medical, Inc.,Quest Diagnostics, Beijing Richen-Force Science & Technology Co., Ltd., Paladin Labs Inc., Beijing Binal Health Bio- Sci & Tech Co., Ltd., AB ANALITICA s.r.l., Otsuka Holdings Co., Ltd., Sercon Group, Campro Scientific GmbH, Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd., Avisa Diagnostics, INFAI GmbH, Meridian Bioscience, Inc., Metabolic Solutions, Inc., Laboratory Corporation of America Holdings, x, Gulf Coast Scientific, Inc., FAN GmbH, and Kizlon Medical